

amdt entered
L/cock 7/26/05

Appl. No. 09/993,295 Amdt. dated Reply to Office action of January 12, 2005

Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

Claim 1. (currently amended). An isolated biopolymer marker peptide consisting of SEQ ID NO:2 ~~diagnostic for insulin resistance.~~

Claims 2-38. (cancelled)

*Insert.
L/cock
7/26/05*

2
Claim 3². (currently amended). A method for ~~diagnosing insulin resistance~~ ^{in a patient sample)} determining the presence of an isolated biopolymer marker consisting of SEQ ID NO: 2 ^{which is linked to insulin resistance} comprising:

(a) obtaining a sample from a patient;

(b) conducting mass spectrometric analysis on said sample in a manner effective to maximize ~~elucidation of discernible~~ analysis of peptide fragments contained therein and comparing mass spectrum profiles of said isolated biopolymer marker consisting of SEQ ID NO:2 to mass spectrum profiles of peptides obtained and analyzed from said sample; and

~~c) comparing mass spectrum profiles of a peptide consisting of SEQ ID NO:2 to mass spectrum profiles of peptides elucidated from said sample, wherein recognition of a mass spectrum profile in the sample displaying the characteristic profile of the mass spectrum profile for the peptide consisting of SEQ ID NO:2 is diagnostic for insulin resistance~~

(c) confirming the presence of said isolated biopolymer marker consisting of SEQ ID NO:2 in said sample displaying a peak profile at about 1812 daltons in said mass spectrum profile;

wherein the presence of said isolated biopolymer marker consisting of SEQ ID No:2 is indicative of a link to insulin resistance.

3

Claim 40. (previously presented). The method of claim 39, wherein the sample is an unfractionated body fluid or a tissue sample.

4

Claim 41. (previously presented). The method of claim 39, wherein said sample is selected from the group consisting of blood, blood products, urine, saliva, cerebrospinal fluid, and lymph.

5

Claim 42. (previously presented). The method of claim 39, wherein said mass spectrometric analysis is selected from the group

consisting of Surface Enhanced Laser Desorption Ionization (SELDI) mass spectrometry (MS), Maldi Qq TOF, MS/MS, TOF-TOF, ESI-Q-TOF and ION-TRAP.

Claim ⁶43. (previously presented). The method of claim 39, wherein said patient is a human.

Claim ⁷44. (currently amended). ~~An insulin resistance diagnostic kit~~ A kit for determining the presence of an isolated biopolymer marker consisting of SEQ ID NO:2 comprising: (a) a peptide consisting of SEQ ID NO:2, and (b) ~~[[and]]~~ an antibody that binds to said peptide in a sample from a patient.

Claim ⁸45. (currently amended). The ~~diagnostic~~ kit of claim 44, wherein said antibody is immobilized on a solid support.

Claim ⁹46. (currently amended). The ~~diagnostic~~ kit of claim 44, wherein said antibody is labeled.